Baker Avenue Asset Management’s Beam Therapeutics BEAM Stock Holding History

Baker Avenue Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-29	Closed	-$697	–	489
2023 Q3	$697	Buy	29 +6	+26%	+$161	﹤0.01%	1355
2023 Q2	$734	Buy	+23	New	+$746	﹤0.01%	1277
2023 Q1	–	Sell	-10	Closed	-$391	–	1625
2022 Q4	$391	Buy	+10	New	+$448	﹤0.01%	1445

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Baker Avenue Asset Management's BEAM Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 29 shares — an estimated $697 sold.

Baker Avenue Asset Management first reported a position in BEAM in Q4 2022 and held it in 3 quarters. The position peaked at $734 in Q2 2023. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

Baker Avenue Asset Management reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 29 Beam Therapeutics shares in Q4 2023, an estimated $697.
Baker Avenue Asset Management first reported a position in Beam Therapeutics in Q4 2022 and held it in 3 quarters.
Baker Avenue Asset Management's Beam Therapeutics position peaked at $734 in Q2 2023.
185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.